Brain Health

The authors urge that screening, prevention, and treatment of anxiety and depression should be important health care priorities for youth who have chronic pain.

The findings demonstrate a need for additional health care provider training and resources for birthing people with intellectual and developmental disabilities.

Those with an aneurysm diagnosis who were younger than 40 years of age were observed to have an even higher risk.

The Alzheimer disease treatment landscape is evolving with new FDA-approved antibody therapies and advancements in biomarker testing to enable earlier diagnosis and intervention.

The study may serve as a foundation for future investigation regarding dietary recommendations to support the treatment of Alzheimer disease.

Findings from 2 large datasets suggest hormone therapy may reduce Alzheimer risk, hippocampal atrophy, and cerebrovascular disease.

Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.

This marks the first FDA-approved systemic therapy for patients with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IHD1) or IDH2 mutation.

Improvements were observed in both the intervention and control group, with those who had self-reported learning difficulties showing the least improvement.

In addition to a rapid deterioration, psychosis in Alzheimer disease can also lead to poorer quality of life, damaged patient-caregiver relationships, and increased isolation.

Edward B. Lee, MD, PhD, also describes how understanding Alzheimer disease requires the integration of multiple fields including genetics, pathology, epidemiology, pharmacology, and physiology.

Study results demonstrated that lecanemab provided sustained benefits over 36 months, such as improved biomarker profiles and slowed cognitive decline compared with placebo.

Tara Spires-Jones, DPhil, FMedSci, discusses how oligomeric tau clumps inside brain synapses, pointing to indirect evidence that it may be progressing through the brain by jumping between connections.

The co-founder, chief science officer, and chairman at Longeveron discusses the findings from the phase 2a trial CLEARMIND, as well as next steps to developing the therapy Lomecel-B.

The findings indicate that zoster vaccine recombinant reduced dementia risk by 17% in an analysis of over 200,000 patients.

Joshua Hare describes how Lomecel-B addresses neuroinflammation, unlike other treatments which typically target amyloid disposition.

The study also found that there were no associations with increased dementia risk when anxiety resolved.

Benzgalantamine (Zunveyl; Alpha Cognition) is a cholinesterase inhibitor indicated for the treatment of mild-to-moderate dementia in adults.

The findings also demonstrate that body dysmorphic disorder is also associated with high levels of comorbid psychopathology, risk, and psychosocial impairment.

Safety and efficacy findings on Lomecel-B will be presented at the upcoming 2024 Alzheimer’s Association International Conference, which will be held July 28 to August 1.

The authors note that the oral, at-home treatment can be a better alternative for patients by reducing inconveniences that come with the injectable and nasal administration methods.

Fish are rich in nutrients that aid in brain development, and the model can help provide more guidance for pregnant individuals when consuming seafood.

Donanemab-azbt is the first and only amyloid plaque targeting therapy that supports stopping therapy when the plaque is removed.

The findings suggest that exploring gender identity is a normal part of adolescent development for some youths.

According to the authors, this vulnerability may stem from either sporadic occurrences of intergenerational chains of childhood abuse.